mrrse

Auto-Injectors Market Assessment Covering Growth Factors and Upcoming Trends by 2026 End

Mar 27th 2019 at 1:06 AM

Looking at the current market trends as well as the promising demand status of the “Auto-Injectors Market” it can be projected that the future years will bring out positive outcomes. This research report added by MRRSE on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application; assisting them to draw conclusions out of this intelligent research report.

Request Free sample report @ https://www.mrrse.com/sample/2999

Auto-injectors are pen like devices used to deliver a fixed dose of drug to patients and are intended for self-administration. Auto-injectors are gradually becoming the gold-standard in the treatment of various indications like anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. Most of the auto-injectors are spring loaded, and the procedure is relatively simple. These are specialised instruments that can be used to avoid needle stick injury and reduce needle phobia among patients. In 1990, the first reusable auto-injector, known as Imigran was launched for the treatment of migraine. Auto-injector manufacturers are focussed on user centric design approaches to enhance ease-of-use and overcome the unwillingness associated with self-administration of intramuscular injections.

Auto-Injectors are expected to present vast opportunities to investors due to high demand in biologics development. Overall revenues from the pre-filled syringes segment is expected to grow during the forecast period due to the rising need for targeted and sustained drug delivery. In September 2015, Bayer Healthcare reported the launch of Betaconnect – the only electronic auto-injector for the treatment of relapsing-remitting multiple sclerosis (RRMS). The procedure does not require a visit to hospitals, clinics, etc. and reduces dependency on healthcare professionals, which is why auto-injectors are becoming a choice of therapy for patients suffering from anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. Increasing adoption of auto-injectors due to benefits such as increased safety, accuracy and minimal discomfort is expected to fuel market revenue growth over the forecast period.

The global auto-injectors market was valued at nearly US$ 1700 Mn in 2016. The market is anticipated to exhibit a CAGR of 15.1% during the forecast period and is projected to be valued at nearly US$ 7,000 Mn by the end of 2026.

Anaphylaxis segment dominated the global auto-injectors market by indication in terms of revenue in 2015 and the trend is projected to sustain throughout the forecast period. Anaphylaxis segment is the most attractive segment with an attractiveness index of 3.55 over the forecast period. Revenue from the anaphylaxis segment is anticipated to register a CAGR of 15% over 2016–2026, to reach more than US$ 6,000 Mn by 2026. Multiple sclerosis segment is expected to be the second most lucrative segment in the global auto-injectors market by indication, with an attractiveness index of 0.2 during the forecast period. Multiple sclerosis segment accounted for 5.3% value share in 2016 and is projected to account for 5.5% share by 2026 end.

Browse Complete Report with TOC @ https://www.mrrse.com/auto-injectors-market-report

Auto-injectors are economical as they reduce about 95% of primary healthcare costs, as there is no need to attend clinics and hospitals for administration of the injection by healthcare professionals. Auto-injectors provide inexpensive home medication and reduce the time consumed at in-patient and out-patient care units. For patients requiring frequent dose administration on weekly and daily basis, the use of auto-injectors reduces the average cost per injection. In addition, auto-injectors reduce needle-stick injuries. Reduction in dependence on healthcare professionals is boosting the use of auto-injectors and is likely to increase the revenue growth of the market over the forecast period.

Some key players in the global auto-injectors market included in this report are Becton, Dickinson and Company, Sanofi, Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc. and Eli Lilly and Company. Mylan N.V. is a leader in the global auto-injectors market in terms of revenue share. Mylan holds a market share of about 83.7% in the global auto-injectors market owing to the fact that the blockbuster product “Epipen” is a widely sold auto-injector and has a tremendous contribution to the global auto-injectors market. Becton, Dickinson and Company is one of the leading manufacturers of refillable auto-injectors focussing on manufacturing Physioject that is compatible with several injectable drugs. In terms of revenue, Becton, Dickinson and Company holds about 8.4% of the global auto-injectors market share owing to a rising adoption of Physioject.

Auto-injectors manufacturers are introducing generic versions in order to reduce the overall cost of the device. In order to better serve anaphylaxis patients with epinephrine at an affordable cost, Mylan N.V. has implemented the decision of introducing the generic version of Epipen at half the price. The initial pack of two was sold at US$ 600 till December 2016 which will be sold at US$ 300 from January 2017. This has increased the affordability of insured as well as non-insured patients to opt for Epipen. This drop in price will increase the penetration of the EpiPen auto-injector, which holds around 90% share of the overall market.

Enquire about this Report @ https://www.mrrse.com/enquiry/2999

About Market Research Reports Search Engine (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: https://www.mrrse.com/

0 comments
Please to comment

sign in

Username
Password
Remember Me


New to IM faceplate? join free!

Lost Password? click here